<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01320696</url>
  </required_header>
  <id_info>
    <org_study_id>831001</org_study_id>
    <nct_id>NCT01320696</nct_id>
  </id_info>
  <brief_title>Reverse Genetic H9N2 Influenza Vaccine Study in Adults</brief_title>
  <official_title>A Randomized, Double Blind, Multi-center, Phase 1/2 Study to Assess Safety and Immunogenicity of Five Dose Levels of a Reverse Genetic (RG) Reassortant H9N2 Pandemic Influenza Vaccine in Healthy Subjects Aged 18 to 49 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ology Bioservices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ology Bioservices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to identify the optimal dose level of a reverse genetic (RG)
      reassortant H9N2 pandemic influenza vaccine for further product development.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with a hemagglutination inhibition (HI) antibody response to the vaccine strain (A/H9N2/chicken/Hong Kong/G9/97) associated with seroconversion 21 days after the second vaccination</measure>
    <time_frame>21 days after 2nd vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects achieving an HI antibody titer &gt;= 1:40 21 days after the second vaccination</measure>
    <time_frame>21 days after 2nd vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and severity of injection site and systemic reactions within 7 days after the first and second vaccination</measure>
    <time_frame>7 days after 1st and 2nd vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects achieving an HI antibody titer &gt;= 1:40 21 days after the first vaccination</measure>
    <time_frame>21 days after 1st vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with antibody response associated with protection 21 days after the first and second vaccination defined as microneutralization (MN) titer &gt;= 1:20</measure>
    <time_frame>21 days after 1st and 2nd vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with antibody response associated with protection 21 days after the first and second vaccination defined as Single Radial Hemolysis (SRH) area &gt;= 25 mm2</measure>
    <time_frame>21 days after 1st and 2nd vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody response 21 days after the first and second vaccination measured by HI, MN and SRH assays</measure>
    <time_frame>21 days after 1st and 2nd vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fold increase of antibody response 21 days after the first and second vaccination as compared to baseline measured by HI, MN and SRH assays</measure>
    <time_frame>21 days after 1st and 2nd vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with seroconversion (as defined for the primary immunogenicity endpoint) measured by HI assay 21 days after the first vaccination as compared to baseline</measure>
    <time_frame>21 days after 1st vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with seroconversion defined as a minimum fourfold increase in titer measured by MN assay 21 days after the first and second vaccination as compared to baseline</measure>
    <time_frame>21 days after 1st and 2nd vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with seroconversion as measured by SRH assay 21 days after the first and second vaccination</measure>
    <time_frame>21 days after 1st and 2nd vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with antibody response associated with protection 180 days after the first vaccination as measured by HI, MN and SRH assays</measure>
    <time_frame>180 days after 1st vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody response 180 days after the first vaccination measured by HI, MN and SRH assays</measure>
    <time_frame>180 days after 1st vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fold increase of antibody response 180 days after the first vaccination as compared to baseline measured by HI, MN and SRH assays</measure>
    <time_frame>180 days after 1st vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with fever, malaise and shivering with onset within 7 days after the first and second vaccination</measure>
    <time_frame>7 days after 1st and 2nd vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse events (AEs) observed during the entire study period</measure>
    <time_frame>Entire study period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">275</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 subjects will be randomized 1:1:1:1:1 to 5 dose groups (10 subjects per treatment group) to receive 2 intramuscular injections of RG reassortant A/H9N2 influenza vaccine on Day 1 and Day 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After a safety data review of the first 50 subjects, a further 225 subjects will be randomized 1:1:1:1:1 to 5 dose groups and will receive 2 intramuscular injections of RG reassortant A/H9N2 influenza vaccine on Day 1 and Day 22</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Reverse Genetic (RG) reassortant A/H9N2 influenza vaccine</intervention_name>
    <description>Two intramuscular vaccinations; 5 dose groups: 3.75 µg, 7.5 µg, 15 µg, 30 µg or 45 µg HA antigen (strain A/H9N2/chicken/Hong Kong/G9/97; non-adjuvanted formulation</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is 18 to 49 years of age, inclusive, on the day of screening

          -  Subject has an understanding of the study and its procedures, agrees to its
             provisions, and gives written informed consent prior to study entry

          -  Subject is generally healthy, as determined by the investigator's clinical judgement
             through collection of medical history and performance of a physical examination

          -  Subject is physically and mentally capable of participating in the study as determined
             by the investigator

          -  Subject agrees to keep a daily record of symptoms for the duration of the study

          -  If female of childbearing potential, subject presents with a negative urine pregnancy
             test within 24 hours prior to first vaccination and agrees to employ adequate birth
             control measures for the duration of the study. For the purposes of this study at
             least one of the following types of US Food and Drug Administration (FDA) approved
             birth control measures shall be applied through completion of the Day 181 study visit:

               -  Hormonal types of birth control (such as implants or birth control pills) or an
                  intrauterine device

               -  A barrier type of birth control measure (i.e. condoms, diaphragms, cervical caps,
                  etc.)

        Exclusion Criteria:

          -  Subject has a history of exposure to H9N2 influenza virus or a history of vaccination
             with an H9N2 influenza vaccine

          -  Subject is at potential occupational risk of contracting H9N2 influenza infection
             (e.g. poultry workers)

          -  Subject currently suffers from or has a history of a significant (requiring
             hospitalization or change in intervention in past 6 months)neurological,
             cardiovascular, pulmonary (including asthma), hepatic, rheumatic, autoimmune,
             hematological, metabolic or renal disorder such as but not limited to: multiple
             sclerosis, lupus, Guillain-Barre syndrome as determined by the investigator

          -  Subject has a body temperature of &gt;= 100.4 degrees Fahrenheit (&gt;= 38.0 degrees
             Celsius) on the day of vaccination, by oral measurement. [NOTE: Subjects meeting this
             exclusion criterion may be rescheduled for vaccination and study entry at a later date
             provided: 1) body temperature measured orally has decreased to &lt; 100.4 degrees
             Fahrenheit (&lt; 38.0 degrees Celsius); 2) all other inclusion/exclusion criteria are
             met; 3) the rescheduled date is no more than 14 days past the initial screening
             assessments and date; and 4) the study site is still enrolling subjects and
             randomization is not closed]

          -  Subject has a Body Mass Index (BMI) &gt;= 35

          -  Subject has hypertension at screening that is graded as greater than Stage 1 (defined
             as a systolic pressure &gt; 159 or diastolic pressure &gt; 99 while seated and at rest
             (measurement shall be repeated twice before subject is excluded)

          -  Subject has clinically significant abnormal laboratory values at screening as
             determined by the investigator

          -  Subject tests positive for Human Immunodeficiency Virus (HIV), Hepatitis B surface
             Antigen (HBsAgs) or Hepatitis C Virus (HCV)

          -  Subject has any medically diagnosed or suspected immune deficient condition based on
             medical history and physical examination as determined by the investigator

          -  Subject has an immune compromising condition or disease, or is currently undergoing a
             form of treatment or was undergoing a form of treatment within 30 days prior to study
             entry that can be expected to influence immune response. Such treatment includes, but
             is not limited to, systemic or high dose inhaled (&gt; 800 μg/day of beclomethasone
             dipropionate or equivalent) corticosteroids, radiation treatment or other
             immunosuppressive or cytotoxic drugs (use of inhaled and nasal steroids will be
             permitted)

          -  Subject has a history of severe (required immediate medical life threatening treatment
             and/or hospitalization) allergic reactions or anaphylaxis as determined by the
             investigator

          -  Subject has a rash, dermatologic condition or tattoos which may interfere with
             injection site reaction rating as determined by the investigator

          -  Subject has received any blood products (e.g. blood transfusion or immunoglobulins)
             within 90 days prior to study entry

          -  Subject has donated one or more units of blood (approximately 450 mL) or plasma within
             30 days prior to study entry

          -  Subject has received any live vaccine within 4 weeks or an inactivated vaccine or a
             subunit vaccine within 2 weeks prior to vaccination in this study

          -  Subject has a functional or surgical asplenia

          -  Subject has a positive urine drug screen (unless the subject is currently prescribed
             the drug detected by a licensed health care provider and the continued administration
             of the drug would not otherwise exclude the subject from participation)

          -  Subject has a known or suspected problem with alcohol or drug abuse as determined by
             the investigator

          -  Subject is currently enrolled or has participated in another clinical study involving
             an investigational products (IP) or device within 30 days prior to study enrollment or
             is scheduled to participate in another clinical study involving an IP or device during
             the course of this study

          -  Subject is a member of the team conducting this study or is in a dependent
             relationship with one of the study team members. Dependent relationships include close
             relatives (i.e. children, partner/spouse, siblings, parents) as well as employees of
             the investigator or site personnel conducting the study

          -  If female, subject is pregnant or lactating at the time of study enrollment

          -  Any condition that in the opinion of the investigator would interfere with evaluation
             of the vaccine or interpretation of study results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Izay, MD</last_name>
    <role>Study Director</role>
    <affiliation>Baxter Innovations GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Accelovance</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accelovance</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accelovance</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accelovance</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accelovance</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2011</study_first_submitted>
  <study_first_submitted_qc>March 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2011</study_first_posted>
  <last_update_submitted>October 5, 2015</last_update_submitted>
  <last_update_submitted_qc>October 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

